DAWN
MaterialsDay One Biopharmaceuticals, Inc. Common Stock
Live · XNAS · May 9, Close
What's Moving DAWN Today?
No stock-specific AI insight has been generated for DAWN yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
DAWN News
20 articles- Servier completes the acquisition of Day One BiopharmaceuticalsYahoo Finance·Apr 23, 2026
- A Look At Day One Biopharmaceuticals (DAWN) Valuation After Recent Share Price MomentumYahoo Finance·Mar 12, 2026
- Oracle, Nike upgraded: Wall Street's top analyst callsYahoo Finance·Mar 11, 2026
- Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More247 Wall St·Mar 11, 2026
- Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More247 Wall St·Mar 10, 2026
- Servier’s $2.5B cancer bet underlines a quick oncology growth strategyPharmavoice·Mar 10, 2026
- DAWN Stock Jumps 66% on $2.5B Buyout Offer From ServierYahoo Finance·Mar 9, 2026
- Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD CowenMarketbeat·Mar 9, 2026
- Day One (DAWN) Soars 100% on $2.5-Billion MergerYahoo Finance·Mar 8, 2026
- Servier’s US$2.5b Deal Caps Day One Biopharma’s Oncology UpsideYahoo Finance·Mar 7, 2026
- Investing.com’s stocks of the weekYahoo Finance·Mar 7, 2026
- Day One (DAWN) Climbs to 3-Year High on $2.5-Billion MergerYahoo Finance·Mar 7, 2026
- Stock Market Today, March 6: Energy Stocks Rise as Oil Closes Over $90 on Middle East TensionsMotley Fool·Mar 6, 2026
- US Equity Indexes Fall Amid Jobs Data Surprise, Rising Oil PricesYahoo Finance·Mar 6, 2026
- Day One Skyrockets On Servier's $2.5 Billion Buyout. Could A 'White Knight' Emerge?Yahoo Finance·Mar 6, 2026
- Sector Update: Health Care Stocks Softer Late AfternoonYahoo Finance·Mar 6, 2026
- Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolioYahoo Finance·Mar 6, 2026
- Top Midday Stories: Gap Falls on Fiscal Q4 Results; Shell-Venezuela Oil Deals; Jefferies Calls Western Alliance Suit 'Without Merit'Yahoo Finance·Mar 6, 2026
- This Biopharma Company Is Being Bought for $2.5 Billion. Its Stock Is Up 66%.Yahoo Finance·Mar 6, 2026
- BC-Most Active StocksYahoo Finance·Mar 6, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Day One Biopharmaceuticals, Inc. Common Stock
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.